Literature DB >> 33504454

Methane and fatty acid metabolism pathways are predictive of Low-FODMAP diet efficacy for patients with irritable bowel syndrome.

Ameen Eetemadi1, Ilias Tagkopoulos2.   

Abstract

OBJECTIVE: Identification of microbiota-based biomarkers as predictors of low-FODMAP diet response and design of a diet recommendation strategy for IBS patients.
DESIGN: We created a compendium of gut microbiome and disease severity data before and after a low-FODMAP diet treatment from published studies followed by unified data processing, statistical analysis and predictive modeling. We employed data-driven methods that solely rely on the compendium data, as well as hypothesis-driven methods that focus on methane and short chain fatty acid (SCFA) metabolism pathways that were implicated in the disease etiology.
RESULTS: The patient's response to a low-FODMAP diet was predictable using their pre-diet fecal samples with F1 accuracy scores of 0.750 and 0.875 achieved through data-driven and hypothesis-driven predictors, respectively. The fecal microbiome of patients with high response had higher abundance of methane and SCFA metabolism pathways compared to patients with no response (p-values < 6 × 10-3). The genera Ruminococcus 1, Ruminococcaceae UCG-002 and Anaerostipes can be used as predictive biomarkers of diet response. Furthermore, the low-FODMAP diet followers were identifiable given their microbiome data (F1-score of 0.656).
CONCLUSION: Our integrated data analysis results argue that there are two types of patients, those with high colonic methane and SCFA production, who will respond well on a low-FODMAP diet, and all others, who would benefit a dietary supplementation containing butyrate and propionate, as well as probiotics with SCFA-producing bacteria, such as lactobacillus. This work demonstrates how data integration can lead to novel discoveries and paves the way towards personalized diet recommendations for IBS.
Copyright © 2021 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  Diet; Irritable bowel syndrome; Low-FODMAP; Microbiome

Mesh:

Substances:

Year:  2021        PMID: 33504454     DOI: 10.1016/j.clnu.2020.12.041

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  4 in total

1.  The gut microbiota-bile acid axis links the positive association between chronic insomnia and cardiometabolic diseases.

Authors:  Zengliang Jiang; Lai-Bao Zhuo; Yan He; Yuanqing Fu; Luqi Shen; Fengzhe Xu; Wanglong Gou; Zelei Miao; Menglei Shuai; Yuhui Liang; Congmei Xiao; Xinxiu Liang; Yunyi Tian; Jiali Wang; Jun Tang; Kui Deng; Hongwei Zhou; Yu-Ming Chen; Ju-Sheng Zheng
Journal:  Nat Commun       Date:  2022-05-30       Impact factor: 17.694

2.  Bifidobacterium longum mediated tryptophan metabolism to improve atopic dermatitis via the gut-skin axis.

Authors:  Zhifeng Fang; Tong Pan; Lingzhi Li; Hongchao Wang; Jinlin Zhu; Hao Zhang; Jianxin Zhao; Wei Chen; Wenwei Lu
Journal:  Gut Microbes       Date:  2022 Jan-Dec

Review 3.  Special Diets in Infants and Children and Impact on Gut Microbioma.

Authors:  Elisabetta Di Profio; Vittoria Carlotta Magenes; Giulia Fiore; Marta Agostinelli; Alice La Mendola; Miriam Acunzo; Ruggiero Francavilla; Flavia Indrio; Alessandra Bosetti; Enza D'Auria; Elisa Borghi; Gianvincenzo Zuccotti; Elvira Verduci
Journal:  Nutrients       Date:  2022-08-04       Impact factor: 6.706

4.  Predictors of Symptom-Specific Treatment Response to Dietary Interventions in Irritable Bowel Syndrome.

Authors:  Esther Colomier; Lukas Van Oudenhove; Jan Tack; Lena Böhn; Sean Bennet; Sanna Nybacka; Stine Störsrud; Lena Öhman; Hans Törnblom; Magnus Simrén
Journal:  Nutrients       Date:  2022-01-17       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.